IntuiTap Medical, a company dedicated to enhancing the precision and efficiency of lumbar punctures and intrathecal drug delivery, has named Ric Cote as Executive Chairman of its Board. This appointment strengthens the company’s leadership as it advances its imaging technology for epidurals, lumbar punctures, and intrathecal procedures while entering a new phase of growth.
Mr. Cote brings extensive experience in the medical device sector, with a career that spans company building, commercialization, strategic growth, and successful exits. Most recently, he served as Chief Executive Officer and Board member at Channel Medical Systems, guiding the company through FDA approvals, global regulatory milestones, and multiple financing rounds. Throughout his career, he has held senior executive and board roles supporting medical technology companies from early clinical development through large-scale commercialization and value creation.
Health Technology Insights: CareTrust Acquires $142 Million Mid-Atlantic Nursing Portfolio
Jessica Traver Ingram, Co-Founder and CEO of IntuiTap Medical, said Ric Cote’s experience guiding medical device companies through key inflection points makes him an ideal leader for this stage of IntuiTap’s growth. She noted that his expertise will be invaluable as the company focuses on commercial expansion, strategic partnerships, and long-term value creation.
As Executive Chairman, Mr. Cote will collaborate closely with IntuiTap’s leadership team and Board of Directors to shape corporate strategy, drive commercialization efforts, and support long-term growth initiatives.
Mr. Cote commented, “I am thrilled to join IntuiTap Medical as Executive Chairman. The quality of the leadership team and the uniqueness of the company’s technology impressed me from the start. I look forward to working alongside the team to advance commercialization and create lasting value.”
IntuiTap Medical has received FDA clearance for its bedside imaging technology, which improves procedural accuracy while reducing reliance on blind techniques and fluoroscopy. The company is now focused on expanding clinical adoption, refining its commercial strategy, and establishing strategic partnerships across healthcare systems and the medical device industry.
Health Technology Insights: Natera Launches 21-Gene Fetal Focus Single-Gene NIPT
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
